A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

NCT03560856 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HR+/HER2-negative Breast Cancer
Metastasis

Interventions

DRUG: Fulvestrant + palbociclib

Sponsor

Assistance Publique - Hôpitaux de Paris